A Scientific Statement From the AHA on CV Risk in Nonalcoholic Fatty Liver Disease
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
Triglycerides
Abdominal Obesity and Icosapent Ethyl Among Patients With Elevated Triglycerides
A study was conducted to determine if icosapent ethyl is effected by patient baseline abdominal obesity.
Meaningful Differences in Standard LDL-C Estimate Equations for ASCVD Patients
Researchers assessed potential discordance among the Friedewald, Sampson, and Martin/Hopkins equations used for estimating LDL-cholesterol.
Novel Omega-3 Krill Oil Agent Safe, Decreases Triglycerides in Hypertriglyceridemia
Researchers investigated the efficacy of a new drug containing a naturally derived krill oil mixture for treatment of severe hypertriglyceridemia.
Triglyceride to HDL Ratio May Be Best Lipid Marker for Predicting Death in Type 2 Diabetes
Patients with type 2 diabetes still have a high risk for cardiovascular disease—even after lowering LDL cholesterol.
FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome
“We are extremely disappointed with the FDA’s decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS,” said Akcea CEO, Paula Soteropoulos.
Patient Connectivity Benefits Familial Chylomicronemia Syndrome
Patients with familial chylomicronemia syndrome who were actively connected were also 3 times as likely to report “high” or “extremely high” motivation in managing their own health.
FDA Committee in Favor of Waylivra for Rare Metabolic Lipid Disorder
Antisense technology refers to the use of synthetic nucleic acid sequences to interrupt specific protein production by targeting the corresponding messenger RNA that encodes that protein.
- Loading...
Loading...
Next post in Dyslipidemia
Loading... 
Loading...